NasdaqCM - Nasdaq Real Time Price USD

VYNE Therapeutics Inc. (VYNE)

1.3000
-0.0700
(-5.11%)
At close: May 8 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
501
501
424
477
931
Cost of Revenue
--
--
--
--
3,348
Gross Profit
--
--
--
--
11,407
Operating Expense
44,138
44,138
29,682
34,772
39,842
Operating Income
-43,637
-43,637
-29,258
-34,295
-38,911
Net Non Operating Interest Income Expense
--
--
--
0
-5,610
Other Income Expense
3,834
3,834
1,386
363
-135
Pretax Income
-39,803
-39,803
-27,872
-33,932
-44,656
Tax Provision
4
4
0
13
-448
Net Income Common Stockholders
-39,834
-39,834
-28,452
-23,210
-73,329
Diluted NI Available to Com Stockholders
-39,834
-39,834
-28,452
-23,210
-73,329
Basic EPS
-0.93
-0.93
-2.78
-7.28
-25.56
Diluted EPS
-0.93
-0.93
-2.78
-7.28
-25.56
Basic Average Shares
42,589
42,589
10,273
3,186
2,859.3880
Diluted Average Shares
42,589
42,589
10,273
3,186
2,859.3880
Total Operating Income as Reported
-43,637
-43,637
-29,258
-34,295
-38,911
Total Expenses
44,138
44,138
29,682
34,772
39,842
Net Income from Continuing & Discontinued Operation
-39,834
-39,834
-28,452
-23,210
-73,329
Normalized Income
-39,807
-39,807
-27,872
-33,945
-44,208
Interest Expense
--
--
--
0
5,610
Net Interest Income
--
--
--
0
-5,610
EBIT
-43,637
-43,637
-29,258
-34,295
-39,046
EBITDA
-43,633
-43,633
-29,258
-34,223
-38,937
Reconciled Cost of Revenue
--
--
--
--
3,348
Reconciled Depreciation
4
4
0
72
109
Net Income from Continuing Operation Net Minority Interest
-39,807
-39,807
-27,872
-33,945
-44,208
Total Unusual Items Excluding Goodwill
--
--
--
--
0
Total Unusual Items
--
--
--
--
0
Normalized EBITDA
-43,633
-43,633
-29,258
-34,223
-38,937
Tax Rate for Calcs
0.0002
0.0002
0
0.0002
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CGEM Cullinan Therapeutics, Inc.
7.77
+0.91%
 
NBTX Nanobiotix S.A.
3.3500
+1.21%
 
CMMB Chemomab Therapeutics Ltd.
1.2300
+0.82%
 
PASG Passage Bio, Inc.
0.3466
+1.20%
 
ELDN Eledon Pharmaceuticals, Inc.
3.1700
+5.67%
 
CELC Celcuity Inc.
10.53
+3.44%
 
TRVI Trevi Therapeutics, Inc.
6.60
-0.90%
 
LYTIX.OL Lytix Biopharma AS
5.46
+1.87%
 
SPRB Spruce Biosciences, Inc.
0.0700
-1.27%
 
GYRE Gyre Therapeutics, Inc.
9.48
+7.12%